Cardiac Biomarkers Market Growth Trajectory Through 2024-2033

Spread the love

The Cardiac Biomarkers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cardiac Biomarkers Market:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

According to The Business Research Company’s Cardiac Biomarkers Global Market Report 2024, The cardiac biomarkers market size has grown rapidly in recent years. It will grow from $17.22 billion in 2023 to $19.48 billion in 2024 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increased healthcare expenditure, fda approvals and regulatory support, aging population, awareness programs, high sensitivity troponin tests, increasing cardiovascular diseases.

The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $31.88 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rising burden of chronic diseases, growing emphasis on early disease detection, expansion of geriatric population, emerging markets development, focus on biomarker panels. Major trends in the forecast period include patient-centric healthcare models, ai and machine learning applications, digital health integration, technological innovations in biomarker discovery, multi-marker panels, liquid biopsy in cardiovascular medicine.

The rising prevalence of cardiovascular disorders is expected to propel the growth of the cardiac biomarker market going forward. Cardiovascular disorders are diseases that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. Cardiac biomarkers are released into the bloodstream in response to certain cardiovascular disorders, such as myocardial infarction (heart attack), heart failure, and arrhythmias, that can be measured using laboratory tests, and their levels can provide important diagnostic and prognostic information. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based public agency, coronary artery disease (CAD) was responsible for killing 375,476 people in 2021, and about 1 in 20 adults age 20 and older had CAD. In addition, about 2 in 10 deaths from CAD happen to adults less than 65 years old. Therefore, the rising prevalence of cardiovascular disorders is driving the growth of the cardiac biomarker market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

The cardiac biomarkers market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Technological advancements are a key trend gaining popularity in the cardiac biomarker market. Companies operating in the cardiac biomarker market are adopting new technologies to sustain their position in the market. For instance, in April 2021, Roche Diagnostics, a Switzerland-based healthcare company, introduced five new solutions for two significant cardiac biomarkers, highly sensitive cardiac troponin T (cTnT-hs) and the N-terminal pro-brain natriuretic peptide test (NT-proBNP), using Elecsys technology. These solutions support cardiac risk identification and improve diagnosis and help identify cardiovascular risk, better diagnose patients and support early treatment.

The cardiac biomarkers market report table of contents includes: